Fengning Zhang

AI Summary

→ WHAT IT COVERS McKinsey partner Fengning Zhang analyzes how Asia's share of the global innovative drug pipeline grew from 28% to 43% in five years, with the region contributing 85% of global pipeline growth in 2024. Zhang outlines distinct capabilities across China, Japan, India, South Korea, and Singapore and how global biopharma should respond. → KEY INSIGHTS - **Asia pipeline scale:** Asia now generates two-thirds of global patents and contributed 85% of global innovative drug pipeline growth in 2024. Companies should treat Asia not as a secondary market but as a primary source of pipeline assets, particularly in ADCs, bispecifics, and next-generation modalities, which represent roughly one-third of global phase one and two activity. - **Country-specific strategy:** Each Asian market offers distinct capabilities: China provides clinical scale and speed; Japan contributes Nobel-level basic science and late-stage development; South Korea leads in biologics manufacturing and cell therapy; Singapore functions as a translational research and funding hub; India offers a deep talent pool for global clinical development. Companies should map their R&D gaps to specific markets rather than treating Asia as one region. - **Japan's startup funding model:** Japan's Agency for Medical Research and Development operates a two-to-one non-dilutive matching fund for early-stage biotech startups — for every dollar a VC invests, qualified companies receive two additional dollars from the government. Global investors should monitor similar government co-investment mechanisms across Asia as leading indicators of emerging pipeline quality. - **Four deal structures for accessing Asian assets:** Licensing, strategic co-development partnerships, NewCo spinouts, and direct-to-global self-builds each remain viable paths. Indian pharma companies are already taking portfolio licensing approaches to bring Chinese assets into Southeast Asia, Middle East, Africa, and Latin America — a model other regional players can replicate to monetize cross-border pipeline opportunities. - **Competitive urgency on deal-making:** High-quality Asian assets attract multiple multinational bidders simultaneously. R&D leaders should build on-the-ground scouting teams in China, South Korea, Japan, and Singapore now, then move decisively. Monitoring company representation at ASCO and AACR, upstream research output, and regional capital market activity provides earlier signals than deal counts or valuations alone. → NOTABLE MOMENT A Chinese biotech executive told Zhang that at a 2015 industry conference, every participant — including those working at the front lines of Chinese innovation — dramatically underestimated where China's biopharma sector would stand by 2025, underscoring how linear projections consistently fail to capture the sector's pace. 💼 SPONSORS None detected 🏷️ Asia Biopharma Innovation, China Drug Pipeline, Cross-Border Licensing, Emerging Market Drug Access, Global R&D Strategy